Filing excerpt
Third quarter 2026 GAAP and Non-GAAP diluted EPS include $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc. as compared to $2 million in the third quarter of 2025.
Source: Autobound Signal API · 76 signals tracked for Biogen · updated
Get Biogen's live signals in Claude or ChatGPT, or by API
What changed at Biogen this week? Use Autobound signals for biogen.com.Biogen incurred $284 million of acquired IPR&D, upfront and milestone expense in Q3 2026 primarily related to the stock acquisition of RayThera Inc.
Filing excerpt
Third quarter 2026 GAAP and Non-GAAP diluted EPS include $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc. as compared to $2 million in the third quarter of 2025.
What this signalsIntegration work after a deal often opens needs for new systems and services.
sec-8kacquisitionCompletedGet every 8-K signal for Biogen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/e7b3368d-0230-48dc-b86f-78e9bdae7d69 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.
{
"signal_id": "e7b3368d-0230-48dc-b86f-78e9bdae7d69",
"signal_type": "sec-8k",
"signal_subtype": "acquisitionCompleted",
"detected_at": "2026-11-03T07:06:53.854+00:00",
"company": {
"name": "Biogen",
"domain": "biogen.com"
},
"data": {
"detail": "Biogen incurred $284 million of acquired IPR&D, upfront and milestone expense in Q3 2026 primarily related to the stock acquisition of RayThera Inc. Integration of newly acquired pipeline assets may create opportunities for clinical development, regulatory compliance, and post-merger integration service vendors.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "acquired IPR&D, upfront and milestone expense primarily related to RayThera Inc. acquisition",
"dollar_millions": 284
},
"summary": "Biogen Closes Acquisition of RayThera Inc. Recording $284M in Upfront and IPR&D Expenses",
"excerpts": "Third quarter 2026 GAAP and Non-GAAP diluted EPS include $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc. as compared to $2 million in the third quarter of 2025.",
"relevance": 0.85,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/biib-20261028.htm",
"filing_date": "2026-10-28",
"filing_year": 2026,
"fiscal_year_end": "10/28",
"sales_relevance": "Active integration needs",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/e7b3368d-0230-48dc-b86f-78e9bdae7d69 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.